PeptideCompareSigumir — EU research guide.
Sigumir is a synthetic tetrapeptide (Val-Glu-Pro-Asp) from the Khavinson bioregulator series targeting cartilage and joint tissue, proposed to regulate chondrocyte gene expression. It is studied in the same general category as Cartalax, another connective-tissue bioregulator in the same family.
What is Sigumir?
Sigumir is a synthetic tetrapeptide (Val-Glu-Pro-Asp) from the Khavinson bioregulator series targeting cartilage and joint tissue, proposed to regulate chondrocyte gene expression. It is studied in the same general category as Cartalax, another connective-tissue bioregulator in the same family.
What does the research show?
Published peer-reviewed research is limited to in-vitro studies in rat cartilage cells from the originating research group; the only human reports found are non-peer-reviewed institutional reports. No independently replicated human trial data is publicly available as of mid-2026.
EU legal status
Not approved as a medicine anywhere in the EU. Available from a small number of specialist research vendors for laboratory use only.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ Modelled per compound from molecular structure — chain length, cyclisation, oxidation- and deamidation-prone residues and light sensitivity. Indicative only, not lab-measured per batch.
Sigumir is not yet in our price comparison
We expand EU supplier coverage every month.
References
- Review by the originating group of peptides that steer chondrogenic differentiation of stem cells. It describes the cartilage polypeptide complex (peptides of 75 to 846 Da, including AED) as in-vitro findings only and states a phase 2 trial in Russia without giving results. Linkova N, Khavinson V, Diatlova A, Myakisheva S, Ryzhak G. Peptide Regulation of Chondrogenic Stem Cell Differentiation. Int J Mol Sci. 2023;24(9):8415. DOIPubMed 37176122
- Cell-culture study of a bovine cartilage polypeptide complex and AED in rat chondrocytes from young and old animals. Proliferation rose in both age groups, more in old cells; it is rat cells in a dish, with no human data. Myakisheva S, Linkova N, Polyakova V, Ryzhak G. Peptides of cartilage tissue: regulation of chondrocyte proliferation, geroprotection and prospects for use in osteoarthrosis. Vrach. 2023;(10):46-49. DOI
- Vendor-hosted lecture slides that describe Sigumir as an extract of cartilage and bone of young animals (peptides of 75 to 10,000 Da) and quote small patient series. Not peer reviewed; the original papers behind the figures were not verified. Peptides in complex therapy of musculoskeletal pathology (lecture slides; file name attributes them to Linkova). Hosted on a vendor website, undated, not peer reviewed. Source
- Institutional report of the group's own medical centre with pain and joint-mobility outcomes in osteoarthritis and osteochondrosis. It is listed only to show what human data exist; it is not peer reviewed, not independent and hosted by a vendor. Khavinson V. Clinical study results of peptide bioregulator Sigumir (institutional report of the medical center of the St Petersburg Institute of Bioregulation and Gerontology; 33 treated and 31 control patients, 2005-2006). Hosted on a vendor website, undated, not peer reviewed. Source